The application of positron-emitting molecular imaging tracers in Alzheimer's disease

Molecular Imaging and Biology

Volumn 9, Issue 4, 2007, Pages 204-216

  Cohen, Robert M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Amyloid; Brain imaging; Cholinergic; Opiate; Serotonin

Indexed keywords

1,1' METHYLENE DI (2 NAPHTHOL); 2 (4 AMINOPHENYL)QUINOLINE; 2 (4 METHYLAMINO)PHENYLQUINOLINE; 2 [1 [6 [(2 FLUOROETHYL)METHYLAMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; 3 (2 AZETIDINYLMETHOXY)PYRIDINE F 18; 4 [2 (2 BENZIMIDAZOLYL)ETHENYL] N,N DIETHYLBENZENAMINE; 4 N METHYLAMINO 4' HYDROXYSTILBENE C 11; ALTANSERIN F 18; AMYLOID; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE; BF 126; BF 158; BF 170; CHOLINESTERASE INHIBITOR; CYCLOFOXY; DONEPEZIL; FLUMAZENIL C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; METHYL 4 PIPERIDYL ACETATE C 11; METHYLPIPERIDIN 4 YL PROPIONATE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NAPHTHOL DERIVATIVE; NICOTINE C 11; NONSTEROID ANTIINFLAMMATORY AGENT; PHYSOSTIGMINE C 11; PHYSOSTIGMINE SALICYLATE; PITTSBURGH COMPOUND B C 11; QUINOLINE DERIVATIVE; ST 1859; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; DRUG HALF LIFE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; BRAIN; HUMANS; NEUROFIBRILLARY TANGLES; NEUROTRANSMITTER AGENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; SENILE PLAQUES;

EID: 34249007642     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-007-0094-3     Document Type: Review

References (132)

1. Bowen DM, et al, 1983 Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease J Neurochem 41 266-272
2. Davies P, Maloney AFJ, 1976 Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 2 1403
3. Cross A, 1990 Serotonin in Alzheimer-type dementia and other dementing illnesses Ann N Y Acad Sci. 600 405-415
4. Nitsch RM, 1996 From acetylcholine to amyloid: Neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 5:477-482
5. Nitsch RM, Deng M, Growdon JH, Wurtman RJ, 1996 Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion J Biol Chem 271 4188-4194
6. Nitsch RM, Wurtman RJ, Growdon JH, 1996 Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden Ann N Y Acad Sci 777 175-182
7. Roberson MR, Harrell LE, 1997 Cholinergic activity and amyloid precursor protein metabolism Brain Res Brain Res Rev 25 50-69
8. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH, 1992 Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors Science 258 304-307
9. Hardy JA, Higgins GA, 1992 Alzheimer's disease: The amyloid cascade hypothesis Science 256 184-185
10. Coyle JT, Price PH, DeLong M, 1983 Alzheimer's disease: A disorder of cortical cholinergic innervation Science 219 1184-1189
11. Beach TG, et al. 2000 The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease.J Neuropathol Exp Neurol 59 308-313
12. Arendt T, Bigl V, Tennstedt A, Arendt A, 1984 Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer's disease Neurosci Lett 48:81-85
13. Sims NR, Bowen DM, Davison AN, 1981 [14C]acetylcholine synthesis and [14C]carbon dioxide production from [U-14C]glucose by tissue prisms from human neocortex Biochem J 196:867-876
14. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL, 1987Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study Arch Gen Psychiatry 44 418-426
15. Beach TG, Honer WG, Hughes LH, 1997 Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: The preclinical stage of Alzheimer's disease? Acta Neuropathol (Berl) 93 146-153
16. Davis BM, et al. 1985 Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies. J Am Geriatr Soc 33:741-748
17. DeKosky ST, et al. 2002 Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:143-144
18. Davis K, et al. 1999 Cholinergic markers in elderly patients with early signs of Alzheimer Disease JAMA 281 1401-1406 1401-1406
19. Mesulam M, Shaw P, Mash D, Weintraub S, 2004 Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum Ann Neurol 55 815-828
20. Goekoop R, Scheltens P, Barkhof F, Rombouts SA, 2006 Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - A pharmacological fMRI study Brain 129 141-157
21. Bartus RT, Dean RL, Beer C, Lippa AS, 1982 The cholinergic hypothesis of geriatric memory dysfunction Science 217 408-417
22. Conner JM, Culberson A, Packowski C, Chiba AA, Tuszynski MH, 2003 Lesions of the Basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning Neuron 38 678-680
23. Kilgard MP, Merzenich M, 1998 Cortical map reorganization enabled by nucleus basalis activity Science 279 1714-1718
24. Drachman DA, 1974 Human memory and the cholinergic system Arch Neurol 30 113-121
25. Sarter M, Hasselmo ME, Bruno J, Givens B, 2005 Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection Brain Res Rev 48 98-111
26. Witte EA, Davidson MC, Marocco RT, 1997 Effects of altering brain cholinergic activity on covert orienting of attention: Comparison of monkey and human performance Psychopharmacology 132 324-334
27. Everitt BJ, Robbins TW, 1997 Central cholinergic systems and cognition Annu Rev Psychol 48 649-684
28. Warburton EC, et al. 2003 Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory Neuron 38 987-996
29. Assal F, Cummings JL, 2002 Neuropsychiatric symptoms in the dementias Curr Opin Neurol 15 445-450
30. Mesulam MM, Geula C, 1992 Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex Brain Res 577 112-120
31. Perry EK, Perry RH, Blessed G, Tomlinson BE, 1977 Necropsy evidence of central cholinergic deficits in senile dementia Lancet 1 189
32. Iyo M, et al. 1997 Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease Lancet 349 1805-1809
33. Kuhl DE, et al. 1999 In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease [see comments] Neurology 52 691-699
34. Shinotoh H, et al. 2000 Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography Alzheimer Dis Assoc Disord 14 S114-S118
35. Bohnen NI, et al. 2005 Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease Neurosci Lett 380 127-132
36. Tanaka N, et al. 2001 Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: Methodology of shape analysis and its diagnostic power for Alzheimer's disease J Cereb Blood Flow Metab 21 295-306
37. Herholz K, et al. 2004 In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease Neuroimage 21 136-143
38. Bohnen NI, et al. 2003 Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study Arch Neurol 60 1745-1748
39. Rinne JO, et al. 2003 Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease J Neurol Neurosurg Psychiatry 74:113-115
40. Herholz K, Weisenbach S, Kalbe E, Diederich NJ, Heiss WD, 2005 Cerebral acetylcholine esterase activity in mild cognitive impairment Neuroreport 16 1431-1434
41. Eggers C, Herholz K, Kalbe E, Heiss WD, 2006 Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease Neurosci Lett 408 46-50
42. Corder EH, et al. 1993 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 921-923 (see comments)
43. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA, 2000 Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex Ann Neurol 48 391-395
44. Bohnen NI, et al. 2005 Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease J Neurol Neurosurg Psychiatry 76 315-319
45. Kaasinen V, et al. 2002 Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease J Clin Psychopharmacol 22 615-620
46. Shinotoh H, et al. 2001 Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET Neurology 56 408-410
47. Carson RE, Kiesewetter DO, Jagoda E, Der MG, Herscovitch P, Eckelman WC, 1998 Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: Control and competition studies J Cereb Blood Flow Metab 18 1130-1142
48. Court J, Clementi F, 1995 Distribution of nicotinic subtypes in human brain Alzheimer Dis Assoc Disord 9 6-14
49. Sabbagh MN, et al. 1998 Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease J Neural Transm 105 709-717
50. Nordberg A, et al. 1990 Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography J Neural Transm Park Dis Dement Sect 2 215-224
51. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. 1995 Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains - In vivo assessment using positron emission tomography Alzheimer Dis Assoc Disord 9 21-27
52. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A, 2006 PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease Psychopharmacology (Berl) 188 509-520
53. Marutle A, Warpman U, Bogdanovic N, Lannfelt L, Nordberg A, 1999 Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation J Neurochem 72 1161-1169
54. Svensson AL, Warpman U, Hellstrom-Lindahl E, Bogdanovic N, Lannfelt L, Nordberg A, 1997 Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes Neurosci Lett 232 37-40
55. Nordberg A, et al. 1997 Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment Dement Geriatr Cogn Disord 8 78-84
56. Eriksdotter Jonhagen M, et al. 1998 Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease Dement Geriatr Cogn Disord 9 246-257
57. Rinne JO, Myllykyla TP, Lonnberg P, Marjamaki P, 1991 A postmortem study of brain nicotinic receptors in Parkinson's disease and Alzheimer's disease Brain Res 547 167-170
58. Pimlott SL, et al. 2004 Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: In vitro binding study using 5-[(125)I]-A-85380 Neuropsychopharmacology 29 108-116
59. Perry EK, et al. 1995 Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology Neuroscience 64 385-395
60. Schmaljohann J, et al. 2004 Imaging of central nAChReceptors with 2-[18F]F-A85380: Optimized synthesis and in vitro evaluation in Alzheimer's disease Appl Radiat Isot 61 1235-1240
61. Zubieta JK, et al. 2001 Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET Synapse 39 275-287
62. Cohen RM, Carson RE, Filbey F, Szczepanik J, Sunderland TS, 2006 Age and APOE-epsilon4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP Synapse 60: 86-92
63. Cohen RM, et al. 2003 Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele Synapse 49 150-156
64. Nordberg A, Alafuzoff I, Winblad B, 1992 Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia J Neurosci Res 31 103-111
65. Sparks D, 1989 Aging and Alzheimer's disease. Altered cortical serotonergic binding Arch Neurol 46 138-140
66. Cheng AV, et al. 1991 Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases J Neurol Sci 106 50-55
67. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JA, 1984 Serotonin receptor changes in dementia of the Alzheimer type J Neurochem 43 1574-1581
68. Cross AJ, et al. 1984 Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type J Neurol Sci 64 109-117
69. Blin J, et al. 1993 Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone Brain 116 497-510
70. Meltzer CC, et al. 1999 PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders Am J Psychiatry 156 1871-1878
71. Meltzer CC, et al. 1998 Reduced binding of [18F]altanserin to serotonin type 2A receptors n aging: Persistence of effect after partial volume correction Brain Res 813 167-171
72. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ, 2002 Greater loss of 5-HT(2A) receptors in midlife than in late life Am J Psychiatry 159 430-435
73. Rosier A, et al. 1996 Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging Psychiatry Res 68 11-22
74. Kepe V, et al. 2006 Serotonin 1A receptors in the living brain of Alzheimer's disease patients Proc Natl Acad Sci USA 103 702-707
75. Reiman EM, et al. 1996 Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N Engl J Med 334 752-758
76. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE, 1997 Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease Ann Neurol 42 85-94
77. Braak H, Braak E, 1991 Neuropathological staging of Alzheimer-related changes Acta Neuropath Appl Neurobiol 14 39-44
78. Pazos A, Palacios JM, 1985 Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors Brain Res 346 205-230
79. Katsurabayashi S, Kubota H, Tokutomi N, Akaike N, 2003 A distinct distribution of functional presynaptic 5-HT receptor subtypes on GABAergic nerve terminals projecting to single hippocampal CA1 pyramidal neurons Neuropharmacology 44 1022-1030
80. Dillon KA, Gross-Isseroff R, Israeli M, Biegon A, 1991 Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: Effects of age and alcohol Brain Res 554 56-64
81. Hall H, et al. 1997 Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 Brain Res 745 96-108
82. Pazos A, Probst A, Palacios JM, 1987 Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors Neuroscience 21 97-122
83. Ohyama M, et al. 1999 Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF Ann Nucl Med 13 309-315
84. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE, 1995 Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease Arch Neurol 52 314-317
85. Barg J, et al. 1993 Opioid receptor density changes in Alzheimer amygdala and putamen Brain Res 632 209-215
86. Hiller JM, Itzhak Y, Simon EJ, 1987 Selective changes in mu, delta and kappa opioid receptor binding in certain limbic regions of the brain in Alzheimer's disease patients Brain Res 406 17-23
87. Tariot PN, Sunderland T, Weingartner H, Murphy D, Cohen MR, Cohen RM, 1986 Naloxone and Alzheimer's disease. Cognitive and behavioral effects of a range of doses Arch Gen Psychiatry 43 727-732 727-732 doses of a range of doses Arch Gen Psychiatry 43 727-732
88. Cohen RM, Andreason PJ, Doudet DJ, Carson RE, Sunderland T, 1997 Opiate receptor avidity and cerebral blood flow in Alzheimer's disease J Neurol Sci 148 171-180
89. Hendry SH, Schwark HD, Jones EG, Yan J, 1987 Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex J Neurosci 7 1503-1519
90. Terry RD, Katzman R, 1983 Senile dementia of the Alzheimer type Ann Neurol 14 497-506
91. Shoghi-Jadid K, et al. 2005 Imaging β-amyloid fibrils in Alzheimer's disease: A critical analysis through simulation of amyloid fibril polymerization Nucl Med Biol 32 337-351
92. Shoghi-Jadid K, Barrio J, Kepe V, Huang SC, 2006 Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology Mol Imaging Biol 8 151-162
93. Lockhart A, 2006 Imaging Alzheimer's disease pathology: One target, many ligands Drug Discov Today 11 1093-1099
94. Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A, 2005 Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils J Biol Chem 280 23599-23604
95. Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF, 2004 Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease Brain Res 1025 98-105
96. Lockhart A, et al. 2005 Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils J Biol Chem 280 7677-7684
97. Agdeppa ED, et al. 2001 Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 21:1-5
98. Klunk WE, et al. 2005 Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain J Neurosci 25 10598-10606
99. Toyama H, et al. 2005 PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease Eur J Nucl Med Mol Imaging 32 593-600
100. Klunk WE, et al. 2004 Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 306-319
101. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE, 2003 Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents J Med Chem 46 2740-2754
102. Klunk WE, et al. 2003 The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component J Neurosci 23 2086-2092
103. Bacskai BJ, et al. 2003 Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice Proc Natl Acad Sci USA 100 12462-12467
104. Engler H, et al. 2006 Two-year follow-up of amyloid deposition in patients with Alheimer's disease Brain 129 2856-2866
105. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR, 2000 "Preclinical" AD revisited: Neuropathology of cognitively normal older adults Neurology 55 370-376
106. Hyman BT, Marzloff K, Arriagada PV, 1993 The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution J Neuropathol Exp Neurol 52 594-600
107. Lopresti BJ, et al. 2005 Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: A comparative analysis J Nucl Med 46 1959-1972
108. Archer HA, et al. 2006 Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C-PIB positron emission tomography study Ann Neurol 60 145-147
109. Logan J, et al. 1990 Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects J Cereb Blood Flow Metab 10 740-747
110. Mintun MA, et al. 2006 [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease Neurology 67 446-452
111. Ono M, et al. 2003 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease Nucl Med Biol 30 565-571
112. Verhoeff NP, et al. 2004 In-vivo imaging of Alzheimer disease beta-amyloic with [11C]SB-13 PET Am J Geriatr Psychiatry 12 584-595
113. Ichise M, Meyer JH, Yonekura Y, (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42:755-763
114. Shoghi-Jadid K, et al. 2002 Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease Am J Geriatr Psychiatry 10 24-35
115. Smid LM, et al. 2006 The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases Brain Pathol 16 124-130
116. Small GW, et al. 2006 PET of brain amyloid and tau in mild cognitive impairment N Engl J Med 355 2652-2663
117. Agdeppa ED, et al. 2003 In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl (methyl)amino]-2-naphthyl]ethylidene) malononitrile Neuroscience 117: 723-730
118. Bauer M, et al. 2006 A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease Clin Pharmacol Ther 80 216-227
119. Price JL, Morris J.C. 1999 Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 358-368
120. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC, 2001 Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease Arch Neurol 58 1395-1402
121. Schonheit B, Zarski R, Ohm TG, 2004 Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology Neurobiol Aging 25 697-711
122. Mitchell T, et al. 2002 Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease Ann Neurol 51: 182-189 182-189
123. Okamura N, et al. 2005 Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer's disease J Neurosci 25 10857-10862
124. Chang YS, et al. 2006 Synthesis and evaluation of benzothiophene derivatives as ligands for imaging beta-amyloid plaques in Alzheimer's disease Nucl Med Biol 33 811-820
125. Chandra R, Kung MP, Kung HF, 2006 Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging Bioorg Med Chem Lett 16 1350-1352
126. Ono M, et al. 2006 Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains J Med Chem 49 2725-2730
127. Suemoto T, et al. 2004 In vivo labeling of amyloid with BF-108 Neurosci Res 48 65-74
128. Zeng F, et al. 2006 Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease Bioorg Med Chem Lett 16 3015-3018
129. Kreutzberg G, 1996 Microglia: A sensor for pathological events in the CNS Trends Neurosci 19 312-318 312-318
130. Cagnin A, et al. 2001 In-vivo measurement of activated microglia in dementia Lancet 358 461-467
131. Zakzanis KK, 1998 Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type J Clin Exp Neuropsychol 20 259-269
132. Zakzanis KK, 1998 Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type J Clin Exp Neuropsychol 20 259-269